2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5016 BCOR-PRC1.1 dictates response and resistance to IDH inhibition in AML

Sarah Hanache, PhD, Xiaoyan Zhang, MS2, Hidetaka Uryu, MD, PhD3, Satoko Ogata, PhD4, Ken Furudate5, Zongrui Li6, Abhinav Jain7, Erika Thompson8, Naval Daver, MD9, Gautam Borthakur, MD10, Farhad Ravandi, MD11, Tapan Kadia I, MD12, Guillermo Garcia-Manero, MD13, Courtney DiNardo, MD, MSCE14, Margaret Goodell, PhD15, Koichi Takahashi, MD,PhD16
1 MD Anderson Cancer Center, Houston, Texas, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 MD Anderson Cancer Center, Houston, Texas, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 MD Anderson Cancer Center, Houston, Texas, United States
8 MD Anderson Cancer Center, Houston, Texas, United States
9 MD Anderson Cancer Center, Houston, Texas, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 MD Anderson Cancer Center, Houston, Texas, United States
16 MD Anderson Cancer Center, Houston, Texas, United States

IDH1/2 mutations produce 2-hydroxyglutarate (2HG), resulting in DNA hypermethylation and impaired differentiation in acute myeloid leukemia (AML). Although IDH inhibitors suppress mutant IDH activity, normalize 2HG, and reverse DNA methylation, relapse remains common. BCOR is a core component of the PRC1.1 transcriptional repressor complex, which is recruited to unmethylated CpG islands through KDM2B to establish transcriptional repression. In our previously reported cohort (Wang et al. Nature Commun. 2021), loss-of-function BCOR/BCORL1 mutations emerged in nearly 20% of relapses despite sustained suppression of 2HG and DNA methylation. We therefore investigated whether BCOR is required for IDH inhibition to restore PRC1.1-mediated transcriptional repression and differentiation.

Using isogenic IDH2-R140Q TF-1 cells treated with enasidenib, we integrated EvoC-seq (simultaneous ATGC, 5mC, and 5hmC profiling), BCOR ChIP-seq, and RNA-seq. Enasidenib reversed approximately 87% of IDH2-associated promoter hypermethylation, while restoring promoter 5hmC, which is consistent with the reversal of 2HG-mediated TET inhibition. At baseline, promoter hypermethylation in IDH2-mutant cells was independently associated with reduced BCOR occupancy (OR = 1.76, 95% CI = 1.52-2.05; P = 2.0 × 10-14). Enasidenib restored BCOR occupancy selectively at demethylated promoters. This coordinated promoter demethylation and BCOR re-recruitment were associated with repression of BCOR target genes enriched for developmental pathways, including canonical/noncanonical WNT signaling pathways. Within WNT pathway genes, high promoter 5mC correlated with low BCOR occupancy, and the combined high 5mC/low BCOR occupancy promoter state was associated with increased RNA expression, whereas high promoter 5hmC was associated with preserved BCOR occupancy and lower RNA expression (FDR < 0.049), consistent with the repressive role of BCOR-PRC1.1.

To determine whether BCOR was required for this transcriptional response, we generated BCOR-knockout (KO)/IDH2-R140Q double-mutant TF-1 cells using CRISPR/Cas9. WNT11 was one of the most upregulated genes in double-mutant cells (log2FC = 3.6; FDR = 0.0055) and remained elevated following enasidenib treatment, whereas enasidenib suppressed WNT11 expression in BCOR-intact IDH2-mutant cells. Gene-set enrichment analysis showed persistent stemness and chromatin-regulatory programs despite enasidenib treatment, including the Jaatinen stem signature (NES = 2.1; FDR = 0.00225). Consistent with these transcriptional changes, double-mutant cells showed impaired erythroid differentiation after enasidenib treatment with 56% reduction in CD235a expression (P <0.05) and 242% increase in CD34 expression (P <10-3) compared to BCOR-intact cells.

We also analyzed CRISPR screening data from Steven Chan’s group (Liu et al. Cancer Research 2022) that revealed Bcor as one of the top essential genes in IDH inhibitor-induced differentiation. In the same screen, disruption of canonical (Wnt9b) and noncanonical (Wnt11) WNT pathway components promoted differentiation during IDH inhibitor treatment, supporting our mechanistic findings. Finally, we analyzed BeatAML and Leucegene data and extracted the transcriptional signature distinguishing double-mutant IDH1/2-BCOR AML from IDH1/2-mutant AML (double mutant signature). This patient-derived double-mutant signature was significantly enriched in both our previously published Wang et al. cohort (NES = 2.15; FDR = 8.69 × 10-10) and double-mutant cells (NES = 1.65; FDR = 6.79 × 10-4), demonstrating concordance between experimental and patient-derived data.

In summary, BCOR is required for transcriptional repression and differentiation following IDH inhibition. Although IDH inhibitors reverse promoter hypermethylation and BCOR recruitment, BCOR loss maintains stemness, WNT signaling and impaired differentiation. These findings identify BCOR loss as a potential 2HG-independent mechanism of resistance to IDH inhibitors and WNT signaling as a potential therapeutic target to overcome this resistance mechanism.

Sarah Hanache, PhD: No relevant conflicts of interest to declare.